Year Established :
1978
Total Assets(USD) :
500,000 to 99,999,999
Total Number of Staff :
more than 1000
Other Competitive Advantages :
We have made significant investments in building world class manufacturing infrastructure. We have created large scale fermentation capabilities to support manufacturing of APIs like statins and immunosuppressants. We also built one of India’s largest bio-manufacturing facilities for insulins, monoclonal antibodies and devices. We continue to invest in expanding our manufacturing capacities to address the growing market needs. Our world class state-of-the art manufacturing sites at Bengaluru, Hyderabad, Vizag and Johor, Malaysia have successfully been inspected and approved by global regulators like US FDA, EMA, TGA Australia, ANVISA Brazil, COFEPRIS Mexico and others.
Patents and Copyrights :
We have filed over 1,200 patent applications and hold around 984 patents and 448 trademark registrations globally.
R&D Capacity :
OEM,Own Brand
Annual Turnover(USD) :
500,000 to 99,999,999
Main Sales Markets :
North America,Western Europe,Eastern Europe,Asia,Middle East
Product Range :
GENERIC, BIOSIMILARS, BRANDED FORMULATION, NOVEL BIOLOGICS